Severe systemic Adverse Reactions to Ophthalmic Timolol in a CYP2D6 Homozygous *4 Allele Carrier: A Case Report

Figures & data

Table 1. Substance, dosage and indication of the patient’s medication by the time of cardiovascular adverse drug reactions.

Substance	Dosage (q.d.)	Indication
Timolol, 0.5%	1 drop	Ocular hypertension
Candesartan, 16 mg	1 tablet	Arterial hypertension (stage II)
Atorvastatin, 20 mg	1 tablet	Hyperlipidemia
Acetylsalicyl acid, 100 mg	1 tablet	Secondary prophylaxis of cardiovascular events
Pantoprazole, 40 mg	1 tablet	Prophylaxis NSAID-related gastrointestinal ulcers
Ibuprofen, 600 mg	1 tablet	Chronic pain syndrome (state after accident); arthrosis

q.d.: Daily.

Table 2. Selected results of pharmacogenotyping and phenotype interpretation.

Gene	Variant also tested variants in gene locus	Genotype	Diplotype	Predicted phenotype
ADRB1	rs1801252, rs1801253	A/A (= WT), C/C (= WT)	Not applicable	Substance-specific function
CYP2D6	rs1065852 c.100 C>T (in *4,*10,*114), rs3892097 c.506-1 G>A (in *4) (rs35742686, rs5030655, rs5030867, rs5030865, rs5030656, rs201377835, rs28371706, rs59421388, rs28371725)	T/T, A/A (= WT)	*4/*4	No function (poor metabolizer)
GNB3	rs5443 c.825C>T	C/T	Not applicable	Substance-specific function

WT: Wild-type.

Data sharing statement/data availability statement

The genetic data presented in this study are available on request from the corresponding author. The data are not publicly available for ethical and privacy reasons.